阿扎西奥普林或托法西提尼布作为对皮质类固醇反应性急性严重性结肠炎的维持疗法
Arshdeep Singh1, Arshia Bhardwaj1, Riya Sharma2
1Department of Gastroenterology, Dayanand Medical College and Hospital, Ludhiana, India.
Alimentary pharmacology & therapeutics
|June 20, 2025
概括
托法西替尼比阿扎西奥普林更有效地维持急性严重性结肠炎 (ASUC) 患者的缓解,这些患者对皮质类固醇有反应. 这一发现突出了托法西提尼布作为ASUC更有效的维持疗法选择.
科学领域:
- 胃肠病学 胃肠病学
- 临床药理学 临床药理学
- 免疫学 免疫学 免疫学
背景情况:
- 对于急性严重性结肠炎 (ASUC) 的最佳维持疗法尚未明确定义.
- 确定有效的长期治疗策略对于对初始皮质类固醇治疗有反应的ASUC患者的管理至关重要.
研究的目的:
- 为了比较阿扎西奥普林与托法西提尼布作为维持疗法的疗效和安全性.
- 评估在ASUC患者在皮质类固醇治疗后维持缓解的有效性.
主要方法:
- 使用倾向得分匹配的回顾性队列研究.
- 包括对静脉注射皮质类固醇有反应的成年ASUC患者.
- 主要终点:1年累积无事件生存率;次要终点包括再住院,皮质类固醇再使用,治疗升级,切除术和不良事件.
主要成果:
- 托法西替尼比阿扎西奥普林 (44.0%) 的1年无事件生存率 (75.0%) 显著更高.
- 观察到托法西提尼布的再住院和治疗升级率较低.
- 与阿扎西奥普林相比,托法西提尼布的症状缓解率更高,尽管综合症状和生物标志物缓解率相似.
结论:
- 托法西替尼比阿扎西奥普林更有效地维持类固醇响应ASUC的维持疗法在1年的标志.
- 在这种患者群体中,托法西提尼布是维持缓解的潜在优越选择.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
210
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
210
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
278
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
278
Drugs for Treatment of Ulcerative Colitis in IBD
244
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
244
Inflammatory Bowel Disease IV: Pharmacological Management
204
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
204
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
240
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
240
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
707
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
707


